Source: http://www.google.com/patents/US8092832?dq=6,970,917
Timestamp: 2017-05-29 04:29:13
Document Index: 535028817

Matched Legal Cases: ['art 5', 'art 1', 'art 2', 'art 1', 'art 2', 'art 3', 'art 1', 'art 2', '§505']

Patent US8092832 - Generally linear effervescent oral fentanyl dosage form and methods of ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsFentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral...http://www.google.com/patents/US8092832?utm_source=gb-gplus-sharePatent US8092832 - Generally linear effervescent oral fentanyl dosage form and methods of administeringAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS8092832 B2Publication typeGrantApplication numberUS 12/955,229Publication dateJan 10, 2012Filing dateNov 29, 2010Priority dateDec 31, 2003Fee statusPaidAlso published asCA2548915A1, CA2548915C, CN102078310A, CN102078310B, DE602004031462D1, EP1708686A2, EP1708686A4, EP1708686B1, US7862832, US20050142197, US20050169989, US20110073518, WO2005065319A2, WO2005065319A3Publication number12955229, 955229, US 8092832 B2, US 8092832B2, US-B2-8092832, US8092832 B2, US8092832B2InventorsDerek Moe, Vikas Agarwal, Walib HabibOriginal AssigneeCephalon, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (137), Non-Patent Citations (305), Classifications (15), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetGenerally linear effervescent oral fentanyl dosage form and methods of administering
Summary of the Dose-Normalized Parameters of Serum Fentanyl for Treatments A, C, D and E Serum Fentanyl Treatment A Treatment C Treatment D Treatment E Arith- Arith- Arith- Arith- Pharmacokinetic metic metic metic metic Parameters P-Value Mean SD Mean SD Mean SD Mean SD Cmax/dose . 2.5 0.8 2.1 0.7 3.3 1.0 3.0 1.2 (pg/mL/mcg) AUC (0-t)/dose . 15.4743 5.01901 14.555 4.9771 18.937 5.2597 16.050 5.9180 (pg*hr/mL/mcg) AUC (0-inf)/dose . 16.5851 5.00318 16.179 5.6510 20.779 5.4935 15.637 6.4732 (pg*hr/mL/mcg ln (Cmax/dose) 0.0127 0.8788 0.3115 0.7190 0.3151 1.137 0.3356 1.011 0.3974 Ln(AUC (0-t)/dose) 0.1727 2.690 0.3170 2.625 0.3409 2.901 0.3032 2.706 0.4002 ln(AUC (0- 0.0783 2.765 0.3003 2.725 0.3633 2.998 0.2894 2.691 0.3892 inf)/dose) Treatment A = 1 × 1080 mcg OraVescent Fentanyl Citrate Tablet Treatment C = 1 × 1300 mcg OraVescent Fentanyl Citrate Tablet Treatment D = 1 × 810 mcg OraVescent Fentanyl Citrate Tablet Treatment E = 1 × 270 mcg OraVescent Fentanyl Citrate Tablet The time intervals over Kel values were determined.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS1262888Feb 20, 1917Apr 16, 1918Albert WestlakeMouth-tablet.US2887437Aug 22, 1956May 19, 1959Pfizer & Co CPalatable vitamin tablet containing an amino acidUS3042531Dec 9, 1959Jul 3, 1962Leslie Salt CompanyMethod of making a compressed tabletUS3131123Jan 12, 1960Apr 28, 1964Lab Francais De TherapeutiqueEnteric tablets and manufacture thereofUS3577490Dec 29, 1969May 4, 1971Miles LabEffervescent tablet and process for making sameUS3888976Nov 1, 1973Jun 10, 1975William P MlkvyZinc and strontium ion containing effervescent mouthwash tabletUS3961041Apr 10, 1975Jun 1, 1976Interx Research CorporationEffervescent enteric coated L-dopa formulation and method of using the sameUS3962417Mar 27, 1974Jun 8, 1976Howell Charles JDentifriceUS3972995Apr 14, 1975Aug 3, 1976American Home Products CorporationDosage formUS4147768May 19, 1978Apr 3, 1979Interx Research CorporationEnteric coated digoxin and therapeutic use thereofUS4187286Jan 2, 1979Feb 5, 1980G&W Laboratories, Inc.Contraceptive suppositoryUS4289751Mar 17, 1980Sep 15, 1981Merck & Co., Inc.Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereofUS4370160Jun 27, 1978Jan 25, 1983Dow Corning CorporationProcess for preparing silicone microparticlesUS4443428Jun 21, 1982Apr 17, 1984Euroceltique, S.A.Extended action controlled release compositionsUS4493848Jul 14, 1983Jan 15, 1985The Procter & Gamble CompanyCompositions and methods useful for producing analgesiaUS4503031Mar 12, 1984Mar 5, 1985Glassman Jacob ASuper-fast-starting-sustained release tabletUS4599342Jan 16, 1984Jul 8, 1986The Procter & Gamble CompanyPharmaceutical products providing enhanced analgesiaUS4613497Feb 29, 1984Sep 23, 1986Health Products Development, Inc.Dry, water-foamable pharmaceutical compositionsUS4639368Jun 6, 1985Jan 27, 1987Farmacon Research CorporationChewing gum containing a medicament and taste maskersUS4671953May 1, 1985Jun 9, 1987University Of Utah Research FoundationMethods and compositions for noninvasive administration of sedatives, analgesics, and anestheticsUS4687662Jan 15, 1986Aug 18, 1987Warner-Lambert CompanyTherapeutic effervescent compositionUS4689218Nov 6, 1986Aug 25, 1987Zambon S.P.A.Effervescent composition with analgesic activityUS4717723Oct 8, 1985Jan 5, 1988Reckitt & Colman Products LimitedPharmaceutical compositionsUS4725427Mar 13, 1984Feb 16, 1988Albion International, Inc.Effervescent vitamin-mineral granule preparationUS4753792Nov 10, 1986Jun 28, 1988Aberg TTooth cleaning tabletUS4756710Mar 7, 1986Jul 12, 1988Merck & Co., Inc.pH-Mediated drug delivery systemUS4853211Oct 28, 1987Aug 1, 1989Eisai Co., Ltd.Stable, effervescent vaginal suppositoriesUS4863737Jun 8, 1987Sep 5, 1989University Of UtahCompositions and methods of manufacture of compressed powder medicamentsUS4876039May 19, 1988Oct 24, 1989Dow Corning CorporationProcess for preparing silicone microparticles cured by a Michael addition reactionUS4940588Mar 17, 1988Jul 10, 1990Elan CorporationControlled release powder and process for its preparationUS5002771Feb 6, 1989Mar 26, 1991Rorer Pharmaceutical Corp.Calcitonin suppository formulationsUS5004601Oct 31, 1988Apr 2, 1991Zetachron, Inc.Low-melting moldable pharmaceutical excipient and dosage forms prepared therewithUS5028411Mar 2, 1989Jul 2, 1991National Research Development CorporationPharmaceutical compositionsUS5053396Aug 1, 1990Oct 1, 1991Blass David HTherapeutic compositionUS5055306Oct 20, 1988Oct 8, 1991Aps Research LimitedSustained-release formulationsUS5073374Nov 30, 1988Dec 17, 1991Schering CorporationFast dissolving buccal tabletUS5102665Mar 7, 1991Apr 7, 1992Glaxo Group LimitedPharmaceutical compositionsUS5102666Sep 11, 1990Apr 7, 1992Oramed, Inc.Calcium polycarbophil controlled release composition and methodUS5135752Oct 14, 1988Aug 4, 1992Zetachron, Inc.Buccal dosage formUS5178878Apr 16, 1992Jan 12, 1993Cima Labs, Inc.Effervescent dosage form with microparticlesUS5223264Aug 26, 1991Jun 29, 1993Cima Labs, Inc.Pediatric effervescent dosage formUS5234957Dec 23, 1991Aug 10, 1993Noven Pharmaceuticals, Inc.Compositions and methods for topical administration of pharmaceutically active agentsUS5288497Sep 5, 1989Feb 22, 1994The University Of UtahCompositions of oral dissolvable medicamentsUS5314904Jun 16, 1992May 24, 1994Alfa Wassermann S.P.A.Pharmaceutical compositions containing rifaximin for treatment of vaginal infectionsUS5387420Jan 8, 1993Feb 7, 1995May & Baker Ltd.Morphine-containing efferverscent compositionUS5445827Jul 7, 1993Aug 29, 1995Bayer AktiengesellschaftEffervescent ibuprofen preparationsUS5458879Sep 30, 1994Oct 17, 1995The Procter & Gamble CompanyOral vehicle compositionsUS5464632Nov 29, 1994Nov 7, 1995Laboratoires PrographarmRapidly disintegratable multiparticular tabletUS5468504Feb 28, 1995Nov 21, 1995Laboratoires Glaxo S.A.Effervescent pharmaceutical compositionsUS5501861Sep 6, 1994Mar 26, 1996Takeda Chemical Industries, Ltd.Fast dissolving tablet and its productionUS5503846Mar 17, 1993Apr 2, 1996Cima Labs, Inc.Base coated acid particles and effervescent formulation incorporating sameUS5559096Apr 10, 1992Sep 24, 1996Applied Microbiology, Inc.Pharmaceutical compositions against gastric disordersUS5607697Jun 7, 1995Mar 4, 1997Cima Labs, IncorporatedTaste masking microparticles for oral dosage formsUS5624687Apr 14, 1992Apr 29, 1997Yamanouchi Pharmaceutical Co., Ltd.Quick-dissolution solid preparationUS5626866Oct 17, 1995May 6, 1997Theratech, Inc.Drug-containing adhesive composite transdermal delivery deviceUS5635210Dec 8, 1994Jun 3, 1997The Board Of Regents Of The University Of OklahomaMethod of making a rapidly dissolving tabletUS5646151Mar 8, 1996Jul 8, 1997Adolor CorporationKappa agonist compounds and pharmaceutical formulations thereofUS5656284Apr 24, 1995Aug 12, 1997Balkin; Michael S.Oral transmucosal delivery tablet and method of making itUS5720974Dec 13, 1995Feb 24, 1998Takeda Chemical Industries, Ltd.Fast dissolving tablet and its productionUS5785989Mar 19, 1997Jul 28, 1998University Utah Research FoundationCompositions and methods of manufacturing of oral dissolvable medicamentsUS5807688May 24, 1996Sep 15, 1998Zeneca LimitedCatalytic antibodies for carbamate activation by a non-spontaneous reaction mechanismUS5851553Dec 19, 1996Dec 22, 1998Fuisz Technologies, Ltd.Process and apparatus for making rapidly dissolving dosage units and product therefromUS5853748Feb 24, 1997Dec 29, 1998Cortecs (Uk) LimitedPharmaceutical compositionsUS5900252Nov 6, 1992May 4, 1999Eurand International S.P.A.Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colonUS5952004Mar 17, 1995Sep 14, 1999Shire Laboratories Inc.Emulsified drug delivery systemsUS5958455Feb 9, 1996Sep 28, 1999Quadrant Holdings Cambridge LtdOral solid dosage forms, methods of making same and compositions thereofUS5958458Aug 1, 1995Sep 28, 1999Dumex-Alpharma A/SPharmaceutical multiple unit particulate formulation in the form of coated coresUS6034085Sep 29, 1998Mar 7, 2000Bristol-Myers Squibb Co.Salt form of nefazodone for use in extended release formulationsUS6068853Oct 13, 1995May 30, 2000Novartis CorporationTemporally controlled drug delivery systemsUS6071539Sep 19, 1997Jun 6, 2000Ethypharm, SaEffervescent granules and methods for their preparationUS6106861Dec 5, 1997Aug 22, 2000Laboratoires PrographarmMultiparticulate tablet disintegrating in less than 40 seconds in the mouthUS6117912Apr 28, 1998Sep 12, 2000Somerset Pharmaceuticals, Inc.Sublingual and buccal administration of selegiline for treating certain selegiline-responsive diseases and conditionsUS6129906Oct 25, 1996Oct 10, 2000The Procter & Gamble CompanySilicone containing powdersUS6155423Apr 1, 1998Dec 5, 2000Cima Labs Inc.Blister package and packaged tabletUS6171617Feb 19, 1997Jan 9, 2001Losan Pharma GmbhEffervescent ibuprofen preparation and process for the production thereofUS6190697Oct 26, 1998Feb 20, 2001Gerhard GergelyEffervescent formulation containing plant extractUS6200604 *Jun 8, 1999Mar 13, 2001Cima Labs Inc.Sublingual buccal effervescentUS6242002Mar 26, 1999Jun 5, 2001Arzneimittelwerk Dresden GmbhEffervescent formulationsUS6264981 *Oct 27, 1999Jul 24, 2001Anesta CorporationOral transmucosal drug dosage using solid solutionUS6294192 *Feb 26, 1999Sep 25, 2001Lipocine, Inc.Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agentsUS6316027Sep 21, 2000Nov 13, 2001R. P. Scherer Technologies, Inc.Fast-dissolving dosage forms for dopamine agonistsUS6326360Mar 10, 1999Dec 4, 2001Grelan Pharmaceuticals Co., Ltd.Bubbling enteric coated preparationsUS6326384Aug 24, 2000Dec 4, 2001Robert R. WhittleDry blend pharmaceutical unit dosage formUS6350470Apr 29, 1999Feb 26, 2002Cima Labs Inc.Effervescent drug delivery system for oral administrationUS6368625Aug 11, 1999Apr 9, 2002Cima Labs Inc.Orally disintegrable tablet forming a viscous slurryUS6383471 *Apr 6, 1999May 7, 2002Lipocine, Inc.Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agentsUS6391335Jul 10, 2000May 21, 2002Cima Labs Inc.Effervescent drug delivery system for oral administrationUS6488961Dec 21, 1999Dec 3, 2002Ethypharm, Inc.Effervescent granules and methods for their preparationUS6509036Oct 29, 2001Jan 21, 2003Cima Labs Inc.Effervescent drug delivery system for oral administrationUS6576250Sep 19, 2000Jun 10, 2003Cima Labs Inc.Pharmaceutical compositions for rectal and vaginal administrationUS6641838Oct 29, 2001Nov 4, 2003Cima Labs Inc.Effervescent drug delivery system for oral administrationUS6680071Mar 2, 2000Jan 20, 2004R. P. Scherer Technologies, Inc.Opioid agonist in a fast dispersing dosage formUS6713470 *Jan 22, 2003Mar 30, 2004Ml Laboratories PlcMethod of treatmentUS6759059 *Sep 24, 1999Jul 6, 2004Diabact AbFentanyl composition for the treatment of acute painUS6761910 *Sep 24, 1999Jul 13, 2004Diabact AbPharmaceutical composition for the treatment of acute disordersUS6764696Mar 18, 2003Jul 20, 2004Cima Labs Inc.Effervescent drug delivery system for oral administrationUS6974590 *Feb 20, 2002Dec 13, 2005Cima Labs Inc.Sublingual buccal effervescentUS7670617Sep 8, 2004Mar 2, 2010Cima Labs Inc.Sequential drug delivery systemsUS7858121 *Dec 30, 2004Dec 28, 2010Cima Labs, Inc.Effervescent oral fentanyl dosage form and methods of administering fentanylUS7862832 *Dec 30, 2004Jan 4, 2011Cima Labs, Inc.Generally linear effervescent oral fentanyl dosage form and methods of administeringUS7862833 *Dec 30, 2004Jan 4, 2011Cima Labs, Inc.Effervescent oral opiate dosage forms and methods of administering opiatesUS20010006677Oct 29, 1996Jul 5, 2001Mcginity James W.Effervescence polymeric film drug delivery systemUS20010041165Jun 11, 2001Nov 15, 2001Merck & Co., Inc.Effervescent bisphosphonate formulationUS20020012680 *Jul 2, 2001Jan 31, 2002Patel Mahesh V.Compositions and methods for improved delivery of lipid regulating agentsUS20020110578 *Feb 20, 2002Aug 15, 2002Pather Sathasivan IndiranSublingual buccal effervescentUS20020160991Oct 26, 2001Oct 31, 2002Liming ShaoOrally-bioavailable formulations of fentanyl and congeners thereofUS20030096012 *Mar 14, 2002May 22, 2003Jerome BesseFilm-forming powder, compositions containing it, methods for their preparation and their usesUS20030124191 *Mar 25, 2002Jul 3, 2003Jerome BesseUse of an immediate-release powder in pharmaceutical and nutraceutical compositionsUS20030153592 *Jan 22, 2003Aug 14, 2003Karen JacksonMethodUS20040213855May 24, 2004Oct 28, 2004Diabact AbPharmaceutical composition for the treatment of acute disordersUS20050037072Sep 21, 2004Feb 17, 2005Cima Labs Inc.Pharmaceutical compositions for rectal and vaginal administrationUS20050042281Aug 21, 2003Feb 24, 2005Singh Nikhilesh N.Compositions for delivering therapeutic agents across the oral mucosaUS20050142197Dec 30, 2004Jun 30, 2005Cima Labs Inc.Generally linear effervescent oral fentanyl dosage form and methods of administeringUS20050142198Dec 30, 2004Jun 30, 2005Cima Labs Inc.Effervescent oral fentanyl dosage form and methods of administering fentanylUS20050163838Dec 30, 2004Jul 28, 2005Cima Labs Inc.Effervescent oral opiate dosage forms and methods of administering opiatesUS20050169989Dec 30, 2004Aug 4, 2005Cima Labs Inc.Generally linear effervescent oral fentanyl dosage form and methods of administeringUS20060292219Aug 28, 2006Dec 28, 2006Cima Labs Inc.Sublingual buccal effervescentUS20070036853Sep 15, 2006Feb 15, 2007Cima Labs Inc.Generally linear effervescent oral fentanyl dosage form and methods of administeringCA2211586A1Jan 30, 1996Aug 8, 1996Societe Civile MissionEffervescent composition containing iodinated polyvinylpyrrolidone, and use thereof for disinfection___________________________________________CA2218370CJul 18, 1996Oct 3, 2006Gerhard GergelyChewable tablet with effervescent actionCA2254060CMay 13, 1997May 1, 2007Merck & Co., Inc.Effervescent bisphosphonate formulationCA2326502CMar 20, 1999Aug 5, 2008Asta Medica AktiengesellschaftEffervescent formulationsDE4139883A1Nov 29, 1991Jun 3, 1993Michael Prof Dr DittgenProdn. of bio-adhesive medicament, e.g. oral or vaginal tablet - comprises mixing drug with swellable, bio-adhesive polymer, dispersant and opt. binderEP0197504B1Apr 3, 1986Oct 7, 1992Merck &amp; Co., Inc.Ph-mediated drug delivery systemEP0275834A1Dec 22, 1987Jul 27, 1988Warner-Lambert CompanyContinuous process for producing a comestible tabletEP0361680B1Aug 25, 1989Jul 13, 1994Rhone-Poulenc Rorer LimitedMorphine-containing compositionEP0396335B1Apr 26, 1990Feb 2, 1994Beecham Group p.l.c.Pharmaceutical formulationEP1062952B1Mar 10, 1999Aug 6, 2003Grelan Pharmaceutical Co., Ltd.Bubbling enteric preparationsEP1067905B1Mar 20, 1999Sep 25, 2002VIATRIS GmbH &amp; Co. KGFizzy formulationsFR2732217B1 Title not availableGB1212704A Title not availableGB2307857B Title not availableNL7302521A Title not availableTW200611697A Title not availableWO2004067004A1Jan 15, 2004Aug 12, 2004Orexo AbA rapid-acting pharmaceutical compositionWO2005065318A3Dec 30, 2004Dec 15, 2005Cima Labs IncEffervescent oral opiate dosage formWO2005065319A3Dec 30, 2004Jan 12, 2006Vikas AgarwalGenerally linear effervescent oral fentanyl dosage form and methods of administering* Cited by examinerNon-Patent CitationsReference1Alternative Routes of Drug Administration-Advantages and Disadvantages (Subject Review), American Academy of Pediatrics Committee on Drugs, Pediatrics, vol. 100(1), pp. 143, 147, Jul. 1997.2Alternative Routes of Drug Administration—Advantages and Disadvantages (Subject Review), American Academy of Pediatrics Committee on Drugs, Pediatrics, vol. 100(1), pp. 143, 147, Jul. 1997.3Altomare, E. et al., "Bioavailability of a New Effervescent Tablet of Ibuprofen in Healthy Volunteers", Eur. J. Clin. Pharmacol, vol. 52, pp. 505-506, 1997.4Amighi et al., "Peroral Sustained-Release Film-Coated Pellets as a Means to Overcome Physicochemical and Biological Drug-Related Problems. I. In Vitro Development and Evaluation", Drug Development and Industrial Pharmacy, vol. 24(6), pp. 509-515, 1998.5Answer to 135 Answer to Amended Complaint, Counterclaim by Cephalon Inc., CIMA Labs Inc., (McCann, Douglas)(Entered: May 18, 2009).6Apr. 11, 2011 D15, Order Setting Scheduling Teleconference—Apr. 29, 2011.7Apr. 11, 2011 D97 Fifth Stipulated Amendment to Scheduling Order.8Apr. 15, 2010 D12, Answer to Counterclaims.9Apr. 20, 2010 D13, Order Setting Scheduling Teleconference.10Apr. 27, 2009 Redacted Answer and Counterclaims to Amended Complaint.11Apr. 27, 2011 Annex to Communication.12Apr. 29, 2009 Plaintiff's Response to Invalidity Contentions.13Apr. 29, 2009 Redacted Def Second Suppl. Objection and Response to Plaintiffs First Set of Interrogatories.14Apr. 4, 2011 D94 Redacted D87 Ltr to Mag J. Thynge fr McCann re Discovery Extention—Proposed Order.15Apr. 4, 2011 D94, Redacted D87 Ltr to Mag. J. Thynge fr McCann re Discovery Extension.16Apr. 5, 2011 D95, Redacted D89 Opening Brief iso Motion to Stay—Exh A-B.17Apr. 5, 2011 D95, Reddacted D89, Opening Brief iso Motion to Stay.18Apr. 5, 2011 D96 Redacted D92, Corrected Ltr to Mag J. Thynge fr Poff re Platfs 3-28 Discovery Ltr.19Audus et al., "The Use of Cultured Epithelial and Endothelial Cells for Drug Transport and Metabolism Studies", Pharmaceutical Research, vol. 7(5), pp. 435-451, 1990.20Audus, "Buccal Epithelial Cell Cultures as a Model to Study Oral Mucosal Drug Transport and Metabolism", The University of Kansas, USA, ed., Chptr 6, pp. 101-115, 1996.21Aug. 13, 2010 D25, Order Rescheduling ADR Teleconference-Aug. 23, 2010.22Aug. 13, 2010 D25, Order Rescheduling ADR Teleconference—Aug. 23, 2010.23Aug. 22, 2010 D31, Order setting Teleconference with MJ Thynge.24Aug. 30, 2010 D26, Cephalon Notice of Service re 1 set of Interoggatories and RFPs to Sandoz.25Aug. 30, 2010 D27, 2nd Stipulated Amendment to Scheduling Order re Document Production.26Aug. 31, 2010 D28, Order Scheduling ADR Teleconference Sep. 22, 2010.27Aug. 31, 2010 D29, Sandoz NOS re 1st Set of Interrogatories and RFPs to Cephalon.28Aug. 5, 2010 D23, Order Regarding Discovery Matters-MPT.29Aug. 5, 2010 D23, Order Regarding Discovery Matters—MPT.30Aug. 5, 2010 D24, Order Scheudling ADR Telecon-Aug. 18, 2010.31Aug. 5, 2010 D24, Order Scheudling ADR Telecon—Aug. 18, 2010.32Aungst, "Oral Mucosal Permeation Enhancement: Possibilities and Limitations", Dupont Merck Pharmaceutical Company, Chptr 4, pp. 65-81, 1996.33Barr Pharmaceuticals and Barr Laboratories Answer to Cephalon and CIMA Labs Inc., Case No. 08-cv-00455-JJF (UNA), Document 8, filed Aug. 12, 2008, 18 pages.34Berko et al., "Influence of pH Change on Drug Release from Rectal Suppositories", Die Pharmazie 4, An International Journal of Pharmaceutical Sciences, vol. 55(4), Short Communications, 2 pages, Apr. 2000.35 *Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A, Westerberg M, Nyström C. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci. Nov. 2003;20(3):327-34.36Bredenberg, "New Concepts in Administration of Drugs in Tablet Form", Formulation and Evaluation of a Sublingual Tablet for Rapid Absorption, and Presentation of an Individualized Dose Administration System, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 287, pp. 1-83, 2003.37Bredenberg, Thesis, "New Concepts in Administration of Drugs in Tablet Form" (Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 287) 2003.38Cephalon Inc. and CIMA Labs Inc., v Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Complaint for Patent Infringement, Oct. 29, 2008.39Cephalon Inc. and CIMA Labs Inc., v. Barr Pharmaceuticals, Inc. Barr Pharmaceuticals, LLC, as successor-in-interest to Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Complaint for Patent Infringement, Jan. 30, 2009.40Cephalon v. Barr Answer Affirmative Defenses, and Counterclaims, dated Aug. 12, 2008.41Cephalon v. Watson, Para. IV-Redacted. (2008).42Cephalon, Inc. and CIMA Labs Inc. v. Barr Pharmaceuticals Inc., and Barr Laboratories Inc. Case No. 08-cv-00455 (UNA), answer, affirmative defenses and counterclaims, Sep. 4, 2008.43Cephalon, Inc. and CIMA Labs Inc. v. Barr Pharmaceuticals, Inc. and Barr Laboratories, Inc., Complaint for Patent Infringement, dated Jul. 22, 2008.44Cephalon, Inc. and CIMA Labs Inc. v. Watson Pharmaceuticals Inc. and Watson Laboratories Inc., Complaint for Patent Infringement, Civil Action #08-330, 2008.45Chen Xia Jing et al., "Studies on Formulations of Fentanyl Buccal Adhesive Tablets", Zhongguo Yiyao Gongye Zazhi, vol. 28(3), Abstract, 1997.46Chen Xia Jing et al., "Studies on Formulations of Fentanyl Buccal Adhesive Tablets", Zhongguo Yiyao Gongye Zazhi, vol. 28(3), Article, 1997.47Claim Construction Chart by Cephalon Inc., Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., CIMA Labs Inc., Watson Pharma, Inc., (McCann, Douglas)(Entered: Feb. 12, 2010).48Coluzzi, P.H. et al., "Breakthrough Cancer Pain: A Randomized Trial Comparing Oral Transmucosal Fentanyl Citrate (OTFC®)and Morphine Sulfate Immediate Release (MSIR®) Pain", vol. 91(1-2), pp. 123-130, Sep. 23, 2011.49Complaint filed against Watson Pharmaceuticals Inc., Watson Laboratories Inc.-Magistrate Consent Notice to Pltf. (Receipt No. 152157-filed by Cephalon Inc., CIMA Labs Inc. (Attachments: 1 Exhibit A, #2, Exhibit B, #3 Civil Cover Sheet, #4 Acknowledgment of Consent Form (sns)(Entered Jun. 3, 2008).50Complaint filed against Watson Pharmaceuticals Inc., Watson Laboratories Inc.—Magistrate Consent Notice to Pltf. (Receipt No. 152157—filed by Cephalon Inc., CIMA Labs Inc. (Attachments: 1 Exhibit A, #2, Exhibit B, #3 Civil Cover Sheet, #4 Acknowledgment of Consent Form (sns)(Entered Jun. 3, 2008).51Conine, James W., Special Tablets in Pharmaceutical Dosage Forms: Tablets, vol. 1, 329 (Herbert A. Liebernab et al. eds, 1989).52Darwish et al., "Absolute and Relative Bioavailability of Fentanyl Buccal Tablet and Oral Transmucosal Fentanyl Citrate", J. of Clinical Pharmacology, vol. 47, pp. 343-350, 2007.53Darwish et al., Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers.54Darwish, M. et al., "Pharmacokinetics and Dose Proportionality of Fentanyl Effervescent Buccal Tablets in Healthy Volunteers", Clin. Pharmacokinet, vol. 44(12), pp. 1279-1286, 2005.55Darwish, M. et al., Relative Bioavailability and Dose Proportionality of a Novel Effervescent Form of Fentanyl in Healthy Volunteers [abstract]. 2005 Annual Meeting, American Society of Anesthesiologists: Oct. 22-26, 2005; Atlanta (GA).56Dec. 1, 2010 D54, Sandoz NOS re Objs and Rsps to 30b6 NOD.57Dec. 10, 2010 D56, Order Setting Continued Mediation Conference.58Dec. 22, 2008 Barr Supp. ANDA Notice Letter.59Dec. 23, 2008 Barr lst set of Interrogatories Nos. 1-10 to Plaintiff.60Dec. 29, 2010 D57, Cephalon Amended NOD of Alison Sherwood.61Dec. 6, 2010 D55, Cephalon and CIMA NOS re Resps and Objs to Sandoz 2nd 30b6 NOD.62Declaration re (251 in 1:08-cv-00330-SLR, 118 in 1:09-cv-00724-SLR) Post Trial Brief on Validity of Gregory Booker by Cephalon Inc., CIMA Labs Inc., (Attachments: #1 Exhibits 1-5)(Marsden, William)(Entered: Jul. 30, 2010).63Defendants' Answering Brief in Opposition to Plaintiffs; Motion to Modify Protective Orders to Allow Use of Information Designated by Watson as Confidential to Support a Citizen Petition, dated May 13, 2010.64Degrande et al., "Specialized Oral Mucosal Drug Delivery Systems: Patches", Oral Mucosal Drug Delivery, Chptr 12, pp. 285-313, 1996.65Eichman et al., Dissertation "Mechanistic Studies on Effervescent-Induced Permeability Enhancement", Pharma. Res. vol. 15(6); pp. 925-930, 1998.66Eichman, "Mechanistic Studies on Effervescent-Induced Permeability Enhancement by Jonathan D. Eichman", a dissertation submitted in partial fulfillment of the requirement for the Degree of Doctor of Philosophy (Pharmacy) at the University of Wisconsin-Madison 1997.67Eichman, J.D. et al., "The Influence of In-Vivo carbonation of GI Physiological Processes and Drug Permeability", Eur. J. Pharmaceutics and Biopharmaceutics, vol. 44 pp. 33-38, 1997.68EP Search Report re PCT/US04/43703, dated Nov. 1, 2005.69EP Supplementary Partial Search Report EP04815715 dated Nov. 14, 2007.70EP Supplementary Partial Search Report for EP 04 81 5715, dated Nov. 14, 2007.71Feb. 1, 2011 D61, Order Setting Teleconference to Discuss Feb. 7, 2011 Mediation—Jan. 31, 2011.72Feb. 1, 2011 DXX, Email to Judge Thynge fr Marsden re Parties Availability for Mediation.73Feb. 11, 2009 Barr Response to Cephalon 2nd set of Interrogatories, Nos. 1-11.74Feb. 11, 2011 D68, Cephalon NOS re 3rd Suppl Resp and Obj to Sandoz 1st Rogs.75Feb. 14, 2011 D69, Order Setting Mediation Conference Mar. 23, 2011.76Feb. 14, 2011 D70, Sandoz NOS re 3rd Suppl Resp and Obj to Cephalon 1st Rogs.77Feb. 16, 2009 D01 Civil Cover Cephalon v Sandoz.78Feb. 16, 2009 D01, Civil Cover Cephalon v. Sandoz.79Feb. 16, 2009 D01, Complaint Cephalon v. Sandoz.80Feb. 16, 2009 D01, Complaint Exhibit A.81Feb. 16, 2009 D01, Complaint Exhibit B.82Feb. 16, 2010 D02, Notice Consent and Reference to a Magistrate.83Feb. 16, 2010 D03, Cephalon Corporate Disclosure Statement.84Feb. 16, 2010 D04, CIMA Labs Inc. Corporate Disclosure Statement.85Feb. 16, 2011 D73, Redacted D66 Ltr to Mag J. Thyne fr Marsden re discovery dispute—Exh A-K.86Feb. 16, 2011 D73, Redacted D66 Ltr to Mag J. Thyne frm Marsden re discovery dispute.87Feb. 16, 2011 D74, Cephalon NOD of Jessica Martori.88Feb. 17, 2009 D11 Answer to Counterclaims.89Feb. 17, 2010 D05, Report of Action to USPTO.90Feb. 17, 2010 D06, Proof of Service.91Feb. 17, 2010 D06, Sandoz Summons.92Feb. 17, 2011 D75, Redacted D67, Ltr to Mag J. Thynge fr Shaw re discovery dispute—Exh A-C.93Feb. 17, 2011 D75, Redacted D67, Ltr to Mag. J. Thynge fr Shaw re discovery dispute.94Feb. 17, 2011 D76, Redacted D72, Ltr to Mag J. Thynge fr Shaw re Cephalon Motion to Compel Navinta-related documents.95Feb. 2, 2011 D62, Order Setting Teleconference re Dates for Mediation Feb. 7, 2011.96Feb. 2, 2011 D63, Order Setting Teleconference re Navinta Discovery Issue Feb. 11, 2011.97Feb. 23, 2009 D09 Answer to Complaint with Counterclaims.98Feb. 24, 2011 DO1, Civil Cover Sheet, Cephalon, Inc. and CIMA Labs Inc. v. Mylan Pharma. Inc. and Mylan Inc., Docket Nos. 08-cv-330-SLR and 10-cv-123-SLR.99Feb. 24, 2011 DO1, Complaint for Infringement with Exhibits, Cephalon, Inc. and CIMA Labs Inc., v. Mylan Phama., Inc. and Mylan Inc.100Feb. 24, 2011 DO2, Notice of Availability of Magistrate.101Feb. 24, 2011 DO3, Cephalon Disclosure Statement.102Feb. 24, 2011 DO4, CIMA Labs Inc. Disclosure Statement.103Feb. 24, 2011 DO5, Suppin Info for ANDA Patent Cases.104Feb. 25, 2011 D06, Report of Filing to USPTO.105Feb. 25, 2011 D77, Plaintiff NOS re Opening Expert Reports.106Feb. 28, 2011 D78, Defendant NOS re Expert Report.107Feb. 4, 2009 D89 Redacted D75 Amended Complaint.108Feb. 8, 2011 D64, Cephalon NOD of Sunil Vandse.109Feb. 8, 2011 D65, Cephalon NOD of Matthew Bohlman.110Fentorao® (fentanyl buccal tablet) label, Oct. 2007, 9 pages.111Hagarstrom, "Polymer Gels as Pharmaceutical Dosage Forms", Theses (Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 287), 2003.112Hagerstrom, These "Polymer Gels as Pharmaceutical Dosage Forms", Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 293, Rheological Performance and Physicochemical Interactions at the Gel-Mucus Interface from Formulations Intended for Mucosal Drug Delivery, pp. 622-700, 2003.113Harris et al. "Drug Delivery via the Mucous Membranes of the Oral Cavity", J. Pharm. Sci., Jan. 1992;81(1):1-10. Review. PubMed PMID: 1619560.114Hessel et al., "A Comparison of the Availability of Prochlorperazine Following I.M. Buccal and Oral Administration", Intl. Journ. of Pharma., vol. 52, Issue 2, pp. 159-164, Jun. 1, 1989.115http://chemical1and21.com/industrialchem/inorganic/SODIUM%20sulphate.HTM, sodium sulphate, 2 pages, (2010).116In re Wada and Murphy, Board of Patent Appeals and Interferences, Appeal 2007-3733 (Jan. 14, 2008), 9 pages.117International Search Report dated Jul. 5, 2000.118International Search Report re EP00919523, Nov. 19, 1999.119Jan. 12, 2009 Watson Response to lst set of Interrogatories Nos. 1-11.120Jan. 14, 2011 D59, Fourth Stipulated Amendment to Scheduling Order.121Jan. 19, 2011 D60, Cephalon NOS re Suppl Resps-Objs to Sandoz 30b6 NODs.122Jan. 19, 2011 DXX, Text Order Granting 4th Stip Amendment to Sched Order.123Jan. 26, 2009 Cephalon Response to Barr 1st Set of Interrogatories Nos. 1-10.124Jan. 27, 2009 D10 Answer to Complaint w Counterclaims.125Jan. 30, 2009 D01 Complaint for Patent Infringement.126Jan. 6, 2011 D58, Proposed Stipulated Protective Order.127Jan. 7, 2011 DXX, Signed Protective Order.128Jan. 9, 2009 Barr Response to Plaintiff's 1st set of Interrogatories Nos. 1-10.129Jul. 15, 2008 D12 Watson Pharmaceuticals MTD Pursuant to FRCP 12b 6 and 7.130Jul. 15, 2008 D15 Watson Labs MTD Pursuant to FRCP 12b6 and 7.131Jul. 20, 2010 D21, Order Scheduling ADR Teleconference-Aug. 4, 2010.132Jul. 20, 2010 D21, Order Scheduling ADR Teleconference—Aug. 4, 2010.133Jul. 22, 2008 D18 Redacted D17 Watson Labs Opening Brief iso MTD.134Jul. 22, 2008 D19 Redacted D14 Watson Pharmaceuticals Opening Brief iso MTD.135Jul. 29, 2010 D22, Stipulated Amendment to Scheduling Order re Document Production.136Jun. 2, 2008 D01 Complaint Cephalon v Watson—filed stamped.137Jun. 2, 2008 D05 Report of Filing of an Action.138Jun. 3, 2010 D20, Order Regarding Discovery Matters.139Jun. 6, 2010 DXX, Scheduling Order Entered.140Kellaway et al., "Mucoadhesive Hydrogels for Buccal Delivery", Oral Mucosal Drug Delivery, Chptr 10, pp. 221-237, 1996.141Kramer et al., T.H., Pharmacodynamic Model of the Effects of Morphine and Morphine-6-Glucuronide During Patient Controlled Analgesia [abstract]. Clin. Pharmacol Ther, 1996, 59, 132.142Labroo, R.B. et al., "Fentanyl Metabolism by Human Hepatic and Intestinal Cyctochrome P450 3A4: Implications for Interindividual Variability in Disposition, Efficacy and Drug Interactions", Drug Metab. Dispos., 1997, 25(9), 1072-1080.143Letter from J. Coster to Speaker, Leaker Reid and Director Lew regarding Protecting Funding for FDA Office of Generic Drugs in Final 2011 Budget with Exhibits A-B, dated Mar. 18, 2011.144Lieberman, Herbert A., ed., "Pharmaceutical Dosage Forms—Tablets", vol. 1, 2nd Ed, pp. 372-376, (1989).145Mar. 10, 2010 D07, Stip to Ext Time re Answer to Complaint.146Mar. 10, 2011 D81, Redacted D79 Ltr to Mag J. Thynge fr Marsden—Att 1-6.147Mar. 10, 2011 D81, Redacted D79, Ltr to Mag. J. Thynge fr Marsden re pending motion to compel discovery.148Mar. 11, 2010 DXX, Order re Stip to Extend Time for Sandoz to Answer.149Mar. 11, 2011 D83, Order, Teleconference Transcript Stands as Order of Court re Navinta Discovery Matter.150Mar. 13, 2009 D11 Answer to Counterclaims.151Mar. 17, 2011 D84 Redated D82, Sealed Ltr to Mag J. Thynge fr Shaw re Pltf Mar. 3, 2011 letter.152Mar. 18, 2011 D09, Stipulation to Extend Time for Mylan to Resp to Complaint.153Mar. 22, 2010 D08, Sandoz Answer with Counterclaims.154Mar. 22, 2010 D09, Sandoz Corporate Disclosure Statement.155Mar. 22, 2010 D10, Sandoz Pro Hac Mot re Gargano of McDermott Will.156Mar. 22, 2010 D11, Sandoz Pro Hac Mot re Garcha-Dolkas-Chang-Boyle of McDermott Will.157Mar. 22, 2011 DXX, Order Granting Stip to Extend Time.158Mar. 25, 2011 D10, Substitution of Counsel.159Mar. 25, 2011 D11, Mylan Defs Answer to Complain with Counterclaim.160Mar. 25, 2011 D12, Mylan Pharmaceuticals Disclosure Statement.161Mar. 25, 2011 D13, Mylan Inc. Disclosure Statement.162Mar. 25, 2011 D85, Order Setting Discovery Teleconference with Judge Thynge.163Mar. 25, 2011 D86, Plaintiffs NOS of Williams Rebuttal Expert Report.164Mar. 28, 2011 D88 Plaintiffs Motion to Stay—Proposed Order.165Mar. 28, 2011 D88, Plaintiffs Motion to Stay.166Mar. 29, 2009 Fish & Richardson Letter.167Mar. 29, 2011 D14, Mylan Pro Hac Mot re Figg and Bhatt of Rothwell Figg.168Mar. 29, 2011 D90, Sandoz NOS of Polli Suppl and Rebuttal Expert Reports.169Mar. 29, 2011 D91, Ltr to Mag. J. Thynge fr McCann encl courtesy Mot to Stay.170Mar. 30, 2009 Redacted Cephalon Supplemental Response to 1st Set of Interrogatories.171Mar. 30, 2009 Watson Supplemental Response to 1st Set of Interrogatories.172Mar. 31, 2010 DXX, Text Order re Pro Hac Adm of McDermott Attys for Sandoz.173Mar. 8, 2011 D80, Order Setting Teleconference re Discovery Issue.174Mar. 9, 2011 D07, Executed Summons re Mylan Pharma., served Feb. 25, 2011.175Mar. 9, 2011 D08, Executed Summons re Mylan Inc., served Feb. 25, 2011.176May 11, 2010 D14, Proposed Scheduling Order.177May 11, 2010 D15, Order re Teleconference-Court Docket Error.178May 11, 2010 D15, Order re Teleconference—Court Docket Error.179May 18, 2009 D144 Cephalon Answer to Counterclaims.180May 20, 2010 D16, Final Proposed Scheduling Order.181May 24, 2010 D17, Order re Teleconference-Court Docket Error.182May 24, 2010 D17, Order re Teleconference—Court Docket Error.183May 25, 2010 D18, Notice re Plaintiffs Initial Disclosures.184May 25, 2010 D19, Noticed re Defendants Initial Disclosures.185May 29, 2009 Letter.186May 29, 2009 Redacted Cephalon 2nd Supplemental Response to 1st Set of Interrogatories, Nos. 1-10.187Motion to Dismiss for Failure to State a Claim (Watson Pharmaceuticals, Inc.'s Motion to Dismiss Pursuant to Fed.R. Civ. P. 12(b)(6) and (7)), Motion to Dismiss for Failure to Join a Party-filed by Watson Pharmaceuticals Inc., (Attachments): #1 Text of Proposed Order (Fineman, Steven)(Entered: Jul. 15, 2008).188Motion to Dismiss for Lack of Jurisdiction Over the Person, Motion to Dismiss for Failure to State a Claim; filed by Watson Laboratories Inc. (Attachments: #1 Text of Proposed Order (Fineman, Steven) (Entered: Jul. 15, 2008).189Nishimura et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa VI: Formulation of Effervescent Enteric-Coated Tablets", J. Pharm. Sci. vol. 73(7): pp. 942-946, (1984).190Nov. 1, 2010 D46, Cephalon Sunpoena Executed Oct. 26, 2010 re Navinta.191Nov. 1, 2010 D47, Cephalon NOS re Resps and Objs to Sandoz 30b6 NOD.192Nov. 12, 2010 D49, Cephalon NOS re Suppl Resp to 1st Set of Rogs—Nos. 3 and 5.193Nov. 18, 2010 D50, Sandoz NOS Objs to Cephalon Subpoena to Navinta.194Nov. 18, 2010 D51, Sandoz Not of Subpoenas to Anesta-Coleman-Zhang.195Nov. 24, 2010 D52, NOS re Resps and Objs Sandoz Subpoena to Anesta.196Nov. 24, 2010 D53, NOS re Resps and Objs Sandoz Subpoena to Dennis Coleman.197Nov. 3, 2008 D11, Plaintiff Answer to Counterclaims.198Nov. 5, 2010 D48, Plaintiffs NOS re Objs to Lerner David Subpoenas.199Oct. 1, 2010 D32, Stipulated Amendment to SO re Doc Production and Claim Terms Exchange.200Oct. 12, 2010 D33, Cephalon NOS re Responses and Objections to Sandoz 1st Rogs and RFPs.201Oct. 12, 2010 D34, Sandoz NOS re Responses and Objection to Cephalon 1st Rogs and RFPs.202Oct. 18, 2010 D35, Sandoz NOS re Inventor and 30b6 NODs.203Oct. 18, 2010 D36, Cephalon 30b6 NOD to Sandoz.204Oct. 25, 2010 D37, Order Setting Mediation Conference.205Oct. 25, 2010 D38, Cephalon NOD of Alison Sherwood.206Oct. 25, 2010 D39, Cephalon NOD of Ellen Camos.207Oct. 25, 2010 D40, Cephalon NOD of Indranil Nandi.208Oct. 26, 2010 D41, Sandoz Not of Subpoenas to Lerner David.209Oct. 26, 2010 D42, Cephalon Not of Subpoena to Navinta LLC.210Oct. 27, 2010 D43, Sandoz Not of Subpoena to University of WI-Madison.211Oct. 28, 2010 D44, Sandoz NOS re 2nd Notice of 30b6 to CIMA and Cephalon.212Oct. 28, 2010 D45, Sandoz Not of Subpoena to Jason Garbell.213Oct. 5, 2010 DXX Text Order Granting Stipulated Amendment to Scheduling Order.214Oct. 6, 2011 Impax Laboratories Para IV Patent Certification Notice, ANDA 203357, 38 pages.215Office Action from corresponding European Application 04 815 715, 2008.216Opinion. Signed by Judge Sue L. Robinson on Mar. 11, 2011. (fms)(Entered: Mar. 11, 2011).217Order denying 95 Motion to Dismiss, denying 15 Motion to Dismiss for Lack of Jurisdiction Over the Person Motion to Dismiss for Failure to State a Claim, denying 12 Motion to Dismiss for Failure to State a Claim. Signed by Judge Sue L. Robinson on Apr. 3, 2009. (nmf)(Entered: Apr. 3, 2009).218Palmisano, B.W., Fentanyl ORALET. Division of Anesthesia, Critical Care and Addiction products. Clinical review. Sep. 17, 1999, [online], http://fda.gov/cder/foi/nda/96/020195s02—fentanyl.pdf.219Pather et al., "Buccal Delivery—Enhanced Buccal Delivery of Fentanyl Using the OraVescent Drug Delivery System", Drug Delivery Tech., vol. 1(1), pp. 1-11, Oct. 2001.220Pather, S. et al., Enhanced Buccal Delivery of Fentanyl Using the OraVescent Drug Delivery System [online]. Drug Delivery Tech. Oct. 1, 2001, (1): 54-7. Available at URL:http://drugdeliverytech.com/cgi-bin/issues.cgi?idissue=1 [Accessed Jun. 23, 2001].221Portenoy, R.K. et al., "Breakthrough Pain: Definition, Prevalence and Characteristics", Pain, vol. 41(3), pp. 273-281, 1990.222Post Trial Brief on Validity (Responsive) by Cephalon Inc., CIMA Labs Inc., (Marsden, William)(Entered: Jul. 30, 2010).223Prescribing Information: Actiq® (Oral Transmucosal Fentanyl Citrate). Physicians' Desk References®. 58th ed. Montvale, N.J.: Medical Economics Company, Inc., pp. 1151-1155, 2004.224Prescribing Information: Kadian® (Morphine Sulfate Sustained Release Capsules) Physicians' Desk Reference®. 59th ed. Montvale, NJ: Medical Economics Company, Inc.; pp. 569-573, 2005.225Ranade, "Drug Delivery Systems Part 5B. Oral Drug Delivery", The Journal of Chemical Pharmacology, vol. 31, pp. 98-115, Feb. 1991.226Rassing, "Specialized Oral Mucosal Drug Delivery Systems: Chewing Gum", Oral Mucosal Drug Delivery, Ch. 13, pp. 319-353, 1996.227Rathbone et al., "In Vivo Techniques for Studying the Oral Mucosal Absorption Characteristics of Drugs in Animals and Humans", Oral Mucosal Delivery, Ch. 7, pp. 121-151, 1996.228Rathbone et al., "Systemic Oral Mucosal Drug Delivery and Delivery Systems", Oral Mucosal Drug Delivery, Ch. 11, pp. 241-275, 1996.229Redacted Version 126 Declaration, by Watson Pharma, Inc., Watson Pharmaceuticals Inc., Watson Laboratories Inc., (Attachments: #1 Exhibit 1-12)(Fineman, Steven)(Entered: Apr. 8, 2009).230Redacted Version 261 Post Trial Brief (Defendants' Reply Post-Trial Brief) by Watson Laboratories Inc, Watson Pharma Inc., Watson Pharmaceuticals Inc., (Hatcher, Laura)(Entered: Aug. 20, 2010).231Redacted Version of (111 in 1:09-cv-00724-SLR, 244 in 1:08-cv-00330-SLR) Post Trial Brief by Cephalon Inc., CIMA Labs Inc., (McCann, Douglas)(Entered: Jul. 6, 2010).232Redacted Version of (160 in 1:09-cv-00724-SLR) Opening Brief in Support,, (293 in 1:08-cv-00330-SLR) Opening Brief in Support,, of Motion to Strike Defendants' Notice of Subsequent Authority by Cephalon Inc., CIMA Labs Inc., (McCann, Douglas)(Entered: Jan. 20, 2011).233Redacted Version of (163 in 1:09-v-00724-SLR, 296 in 1:08-cv-00330-SLR) Declaration, of Chiemi D. Suzuki in Support of Watson's Opposition to Plaintiffs' Motion to Strike Defendants' Notice of Subsequent Authority Pursuant to Local Rule 7.1.2(b), or in the Alternative to Reopen the Record by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Exhibit 1-2, #2 Exhibit 3, Part 1, #3 Exhibit 3, Part 2, #4 Exhibit 4) (Fineman, Steven)(Entered: Jan. 25, 2011).234Redacted Version of (164 in 1:09-cv-007204-SLR) Declaration, of Janie Gwinn in Support of Watson's Opposition to Plaintiffs' Motion to Strike Defendants' Notice of Subsequent Authority Pursuant to Local Rule 7.1.2(b) or in the Alternative to Reopen the Records by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Exhibits 1-2)(Fineman, Steven)(Entered: Jan. 25, 2011).235Redacted Version of (174 in 1:09-cv-00724-SLR) Answering Brief in Opposition, (307 in 1:08-cv-00330-SLR) Answering Brief in Opposition to Defendants' Motion to Vacate the Oct. 28, 2010 Order by Cephalon Inc., CIMA Labs Inc., (Booker, Gregory)(Entered: Feb. 4, 2011).236Redacted Version of (176 in 1:09-cv-00724-SLR) Declaration, (308 in 1:08-cv-00330-SLR) Declaration, of William Campbell in Support of Answering Brief in Opposition to Defendants' Motion to Vacate the Oct. 28, 2010 Order by Cephalon Inc., CIMA Labs Inc., (Booker, Gregory)(Entered: Feb. 4, 2011).237Redacted Version of (210 in 1:08-cv-00330-SLR) Claim Construction Answering Brief, (80 in 1:09-cv-00724-SLR) Claim Construction Answering Brief by Cephalon Inc., CIMA Labs Inc., (Attachments: #1 Exhibits A-E)(Marsden, William)(Entered: Apr. 6, 2010).238Redacted Version of (215 in 1:08-cv-00330-SLR) Reply Brief, (86 in 1:09-cv-00724-SLR) Reply Brief, in Support of Plaintiffs' Motion to Modify the Protective Orders to Allow Use of Information Designated by Watson as Confidential to Support a Citizen Petition by Cephalon Inc., CIMA Labs Inc., (Marsen, William)(Entered: Apr. 8, 2010).239Redacted Version of (294 in 1:08-cv-00330-SLR) 161 in 1:09-cv-00724-SLR) Declaration, of Gregory R. Booker in Support of Motion to Strike Defendants' Notice of Subsequent Authority by Cephalon Inc., CIMA Labs Inc., (Attachments: #1 Exhibits A-C)(McCann, Douglas)(Entered: Jan. 20, 2011).240Redacted Version of (306 in 1:08-cv-00330-SLR) Reply Brief,,,(172 in 1:09-cv-00724-SLR) Reply Brief in Support of Motion to Strike Defs' Notice of Subsequent Authority Pursuant to Local Rule 7.1.2(b), or in the Alternative, to Reopen the Record (With Watson's Requested Redacations) by Cephalon Inc., CIMA Labs Inc., (Attachments: #1 Exhibits 1-3)(Booker, Gregory)(Entered: Feb. 4, 2011).241Redacted Version of (309 in 1:08-cv-00330-SLR) Declaration, (175 in 1:09-cv-00724-+SLR) Declaration of Randy J. Bradway in Support of Answering Brief in Opposition to Defendants' Motion to Vacate the Oct. 28, 2010 Order by Cephalon Inc., CIMA Labs Inc., (Attachments: #1 Exhibits 1-4)(Booker, Gregory)(Entered: Feb. 4, 2011).242Redacted Version of (59 in 1:09-cv-00724-SLR) Claim Construction Opening Brief, (194 in 1:08-cv-00330-SLR) Claim Construction Opening Brief of Defendant Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc., by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., Watson Pharma, Inc., (Hatcher, Laura)(Entered: Mar. 12, 2010).243Redacted Version of (60 in 1:09-cv-00724-SLR) Declaration, (195 in 1:08-cv-00330-SLR) Declaration of Steven J. Fineman in Support of Defendant Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc.'s Opening Claim Construction Brief by Watson Laboratories, Inc., Watson Pharma, Inc.'s Watson's Pharmaceuticals Inc.'s, (Attachments: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3, #4 Exhibit 4, #5 Exhibit 5, #6 Exhibit 6, #7 Exhibit 7, #8 Exhibit 8, #9 Exhibits 9-15, #10 Exhibit 16, #11 Exhibit 17, #12 Exhibit 18, #13 Certificate of Service).244Redacted Version of 117 Answering Brief in Opposition, to Watson Pharma, Inc's Motion to Dismiss Counts 1, 2, 4, and 5 of the Amended Complaint Pursuant to Fed. R. Civ. P. 12(b)(6) and (7); and Defendants' Motion to Dismiss Counts 3 and 6 of the Amended Complaint Pursuant to Fed. R. Civ. P. 12(b)(1) by Cephalon Inc., CIMA Labs Inc., (McCann, Douglas)(Entered: Mar. 23, 2009).245Redacted Version of 118 Declaration, of Robert M. Oakes in Support of Plaintiffs' Brief in Opposition to Watson Pharma, Inc.'s Motion to Dismiss Counts 1, 2, 4, and 5 of the Amended Complaint Pursuant to Fed. R. Civ. P. 12(b)(6) and (7); and Defendants' Motion to Dismiss Counts 3 and 6 of the Amended Complaint Pursuant to Fed. R. Civ. P. 12 (b)(1) by Cephalon Inc., CIMA Labs Inc.. (McCann, Douglas)(Entered: Mar. 23, 2009).246Redacted Version of 125 Reply Brief, by Watson Pharma, Inc., Watson Pharmaceuticals Inc., Watson Laboratories Inc., (Fineman, Steven)(Entered: Apr. 8, 2009).247Redacted Version of 14 Opening Brief in Support of Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(6) and (7) by Watson Pharmaceuticals Inc, Watson Laboratories Inc. (Attachments #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3) (Fineman, Steven)(Entered: Jul. 22, 2008).248Redacted Version of 17 Opening Brief in Support, of Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(2) and (6) by Watson Pharmaceuticals Inc., Watson Laboratories Inc. (Attachments: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3) (Fineman, Steven) (Entered: Jul. 22, 2008).249Redacted Version of 193 Claim Construction Opening Brief Plaintiffs' Consolidated Opening Markman Brief by CIMA Labs Inc., Cephalon Inc.,(Attachment: #1 Exhibit A-H)(McCann, Douglas)(Entered: Mar. 12, 2010).250Redacted Version of 211 Claim Construction Answering Brief by Watson Laboratories Inc., Watson Pharma, Inc., Watson Pharmaceuticals Inc., (Hatcher, Laura)(Entered: Apr. 16, 2010).251Redacted Version of 212 Declaration, of Steven J. Fineman in Support of Defendants Answering Claim Construction Brief by Watson Laboratories Inc., Watson Pharma, Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Exhibits A-B)(Hatcher, Laura)(Entered: May 13, 2010).252Redacted Version of 231 Sealed Motion for Limited Admission Defendants Watson Pharmaceuticals, Inc., Watson Laboratories, Inc., and Watson Pharma, Inc.'s Motion to Exclude Certain CO2 Testing and Related Expert Opinions At Trial by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Exhibits 1-4, #2 Text of Proposed Order) (Hatcher, Laura)(Entered: Aug. 13, 2010).253Redacted Version of 234 Proposed Pretrial Order by CIMA Labs Inc., Cephalon Inc., Watson Laboratories Inc., Watson Pharma, Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Exhibits 1-4, #2 Exhibits 5-8, #3 Exhibit 9 part 1, #4 Exhibit 9 part 2, #5 Exhibit 9 part 3, #6 Exhibit 10, #7 Exhibit 11, #8 Exhibits 12-13)(McCann, Douglas)(Entered: Apr. 26, 2010).254Redacted Version of 235 Answering Brief in Opposition, to Defendants; Motion to Exclude Certain CO2 Testing and Related Expert Opinions at Trial by CIMA Labs Inc. Cephalon Inc., (Attachments: #1 Exhibits 1-13)(Marsden, William)(Entered: May 3, 2010).255Redacted Version of 245 Post Trial Brief Defendants' Opening Post-Trial Brief [Public Version] by Watson Laboratories Inc., Watson Pharma Inc, Watson Pharmaceuticals Inc., (Hatcher, Laura)(Entered: Jul. 6, 2010).256Redacted Version of 253 Post Trial Brief by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Hatcher, Laura)(Entered: Aug. 9, 2010).257Redacted Version of 254 Sealed Motion to Strike Expert Testimony by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc.,(Attachments #1 Certification Pursuant to District of Delaware Local Rule 7.1.1, #2 Text of Proposed Order)(Hatcher, Laura)(Entered: Aug. 11, 2010).258Redacted Version of 255 Declaration, of Bryan J. Braunel in Support of Motion to Strike Expert Testimony by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Exhibits 1-15) (Hatcher, Laura)(Entered: Aug. 11, 2010).259Redacted Version of 262 Post Trial Brief by CIMA Labs Inc., Cephalon, Inc., (McCann, Douglas)(Main Document 271 replaced on Aug. 20, 2010)(lid)(Entered: Aug. 20, 2010).260Redacted Version of 263 Declaration of Gregory Booker in Support of Post Trial Reply Brief by CIMA Labs Inc., Cephalon, Inc., (Attachments: #1 Exhibits 1-2)(McCann, Douglas)(Entered: Aug. 20, 2010).261Redacted Version of 264 Answering Brief in Opposition, to Defendants Motion to Strike Expert Testimony by CIMA Labs Inc., Cephalon Inc., (Marsden, William)(Entered: Aug. 20, 2010).262Redacted Version of 265 Declaration, of Gregory Booker in Support of Plaintiffs Brief In Opposition to Defendants Motion to Strike by CIMA Labs Inc., Cephalon Inc., (Attachments: #1 Exhibits A and B)(Marsden, William) (Entered: Aug. 20, 2010).263Redacted Version of 279 Post Trial Brief (Corrected Defendants' Reply Post-Trial Brief) by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Hatcher, Laura)(Entered: Sep. 30, 2010).264Redacted Version of 295 Answering Brief in Opposition, to Plaintiffs' Motion to Strike Defendants' Notice of Subsequent Authority Pursuant to Local Rule 7.1.2(b), or in the Alternative to Reopen the Records by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Fineman, Steven)(Entered: Jan. 25, 2011).265Redacted Version of 298 Sealed Motion to Vacate 290 Memorandum and Order, Defendants' Motion to Vacate the Oct. 28, 2010 Order by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Certification Pursuant to Distric of Delaware Local Rule 7.1.1, #2 Text of Proposed Order)(Hatcher, Laura)(Entered: Feb. 3, 2011).266Redacted Version of 299 Declaration, of Andrew S. Boyer in Support of Watson's Motion to Vacate the Court's Oct. 28, 2010 Order by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Exhibit 1)(Hatcher, Laura)(Entered: Feb. 3, 2011).267Redacted Version of 300 Declaration, of Chiemi D. Suzuki in Support of Defendant's Motion to Vacate the Oct. 28, 2010 Order by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Attachments: #1 Exhibit 1, #2 Exhibit 2 (Part 1 and 2), #3 Exhibit 2 (Part 2 of 2), #4 Exhibit 3)(Hatcher, Laura) (Entered: Feb. 3, 2011).268Redacted Version of 313 Reply Brief in Further Support of its Motion to Vacate the Oct. 28, 2010 Order by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Hatcher, Laura)(Entered: Feb. 11, 2011).269Redacted Version of 315 Declaration of Andrew S. Boyer in Support of Defendants' Reply Brief in Further Support of its Motion to Vacate the Oct. 28, 2010 Order by Watson Laboratories Inc., Watson Pharma Inc., Watson Pharmaceuticals Inc., (Hatcher, Laura)(Entered: Feb. 11, 2011).270Redacted Version of 96 Opening Brief in Support of Its Motion to Dismiss Counts 1, 2, 4, and 5 of the Amended Complaint pursuant to Fed. R. Civ. P. 12(b)(6) and (7) and Defendants' Opening Brief in Support of Their Motion to Dismiss Counts 3 and 6 of the Amended Complaint pursuant to Fed. R. Civ. P. 12 (B)(1) by Watson Pharma, Inc., Watson Pharmaceuticals Inc., Watson Laboratories Inc., (Fineman, Steven) (Entered: Mar. 6, 2009).271Redacted Version of 97 Declaration, of H. Sarah Park dated Feb. 20, 2009 in Support of Watson Defendants' Motion to Dismiss by Watson Pharma, Inc., Watson Pharmaceuticals Inc., Watson Laboratories Inc., (Attachments: #1 Exhibit 1-30)(Fineman, Steven)(entered: Mar. 6, 2009).272Redacted Version of 99 Reply Brief, in Support of its Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(2) and (6) by Watson Pharma, Inc., Watson Pharmaceuticals Inc., Watson Laboratories Inc., (Fineman, Steven)(Entered: Mar. 6, 2009).273Redacted; Watson Itr to Cephalon and CIMA Labs dated Apr. 15, 2008, re: Notification of Certification of Invalidity, Unenforceability and/or Non-Infringement for U.S. Patent Nos. 6,200,604 and 6,974,590.274Reisine, T. et al., "Opioid Analgesics and Antagonists", in Hardman, J.G. et al., editors. Goodman and Gilman's Pharmacologic Basis of Therapeutics. 9th rev. ed. New York: McGraw Hill, pp. 521-555, 1996.275Report to Commissioner of Patents and Trademarks for Patent/Trademark Nos. US 6,200,604 BI; US 6,997,590 B2, (sns) (Entered: Jun. 3, 2008).276Rowe et al., "Handbook of Pharmaceutical Excipients", Fifth Edition, pp. 758-759, 2006.277Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa II: Bioavailability of Marketed Levodopa Preparations in Dogs and Parkinsonian Patients", Journ. of Pharma. Sciences, vol. 69(3), pp. 261-264, Mar. 1980.278Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa IV: Possible Causes of Low Bioavailiability of Oral Levodopa in Dogs", J. Pharm. Sci. vol. 70(7), pp. 730-733, 1981.279Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa V: Absorption and Metabolism of Levodopa in Intestinal Segments of Dogs", Journ. of Pharma. Sciences, vol. 70(10), pp. 1157-1160, Oct. 1981.280Sasahara et al., "Dosage Form Design for Improvement of Bioavailability of Levodopa VI: Formulation of Effervescent Enteric-Coated Tablets", J. Pharm. Sci. vol. 73(7), pp. 942-946, Jul. 1984.281Schenkels et al., "Salivary Mucins: Their Role in Oral Mucosal Barrier Function and Drug Delivery", Oral Mucosal Drug Delivery, Ch. 9, pp. 191-211, 1996.282Scott, J.C. et al., "EEG Quantitation of Narcotic Effect: The Comparative Pharmacodynamics of Fentanyl and Alfentanil", Anesthesiology, vol. 62(3), pp. 234-241, 1985.283Sealed Opening Brief in Support re 12 Motion to Dismiss for Failure to State a Claim (Watson Pharmaceuticals, Inc.'s Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(6) and (7)) Motion to Dismiss for Failure to Join a Party Motion to Dismiss for Failure to State a Claim (Watson Pharmaceuticals, Inc'S Motion to Dismiss Pursuant to Fed. R. Civ. P. 12(b)(6) and (7) filed by Watson Pharmaceuticals Inc. Answering Brief/Response due date per Local Rules is Aug. 1, 2008. (Fineman, Steven)(Entered: Jul. 15, 2008).284Sealed Opening Brief in Support re 15 Motion to Dismiss for Lack of Jurisdiction Over the Person Motion to Dismiss for Failure to State a Claim filed by Watson Laboratories Inc., Answering Brief/Response due date per Local Rules is Aug. 1, 2008. (Fineman, Steven)(Entered Jul. 15, 2008).285Sep. 1, 2010 D30, Cephalon Notice of Entry of Appearance of Compton.286Sep. 28, 2011 Mylan Ltr re: Notice of Paragraph IV Certification.287Soracuchart et al., "Drug Release from Spray Layered and Coated Drug-Containing Beads: Effects of pH and Comparison of Different Dissolution Methods", Drug Development and Industrial Pharmacy, vol. 25(10), pp. 1093-1098, 1999.288Soskolone et al., "Intra-periodontal Pocket Drug Delivery Systems", Oral Mucosal Drug Delivery, Chptr. 14, pp. 359-373, 1996.289Squier et al., "Structure and Function of the Oral Mucosa and Implications for Drug Delivery", Oral Mucosal Drug Delivery, Chprt. 1, pp. 1-19, 1996.290Stanley et al., "Novel Delivery Systems: Oral Transmucosal and Intranasal Transmucosal", Journ. of Pain and Symptom Management, vol. 7(3), pp. 163-171, Apr. 1992.291Sterne, Kessler, ANDA Letter dated Jun. 9, 2008.292Sterne, Kessler, Letter dated Jun. 27, 2008.293Streisand et al., "Buccal Absorption of Fentanyl is pH-Dependent in Dogs", Anesthesiology, vol. 82(3), pp. 759-764, (Mar. 1995).294Streisand, J.B. et al., "Absorption and Bioavailability of Oral Transmucosal Fentanyl Citrate", Anesthesiology, vol. 75 (2), pp. 223-229, 1991.295Streubel et al., "pH-Independent Release of a Weakly Basic Drug from Water-Insoluble and Soluble Matrix Tablets", Journ. of Controlled Release, vol. 67, pp. 101-110, 2000.296Supplementary Search Report, EP 00 92 6341, dated Nov. 23, 2005.297Supplementary Search Report, EP 00 926341, dated Nov. 23, 2005.298The Alcohol and Other Drug Thesaurus, National Institute of Health, National Institute on Alcohol Abuse and Alcoholism (Third Edition, 2000, U.S. Dept. of Health and Human Services).299U.S. Appl. No. 09/661,693, filed Sep. 14, 2000.300Watson, Notification of Certification of Invalidity, Unenforceability and/or Non-Infringement for U.S. Patent Nos. 6,200,604 and 6,974,590 Pursuant to §505(j)(2)(B)(iv) of the Federal Food, Drug, and Cosmetic Act, Letter dated Apr. 15, 2008.301Weatherell et al., "The Flow of Saliva and its Influence on the Movement, Deposition, and Removal of Drugs Administered to the Oral Cavity", Oral Mucosal Drug Delivery, Chptr. 8, pp. 157-187, 1996.302Weinburg et al., "Sublingual Absorption of Selected Opioid Analgesics", Clin. Pharma., vol. 44(3), pp. 335-342, Sep. 1988.303Wertz et al., "Biochemical Basis of the Permeability Barrier in Skin and Oral Mucosa", Oral Mucosal Drug Delivery, Chptr. 2, pp. 27-41, 1996.304Zhang et al., "In Vitro Methods for Measuring Permeability of the Oral Mucosal", Oral Mucosal Drug Delivery, Chptr. 5, pp. 85-97, 1996.305Zhang et al., "Routes of Drug Transport Across Oral Mucosa", Oral Mucosal Drug Delivery, Chptr 3, pp. 51-61, 1996.* Cited by examinerClassifications U.S. Classification424/464, 424/434, 424/465, 424/466International ClassificationA61K31/445, A61K9/20, A61K9/46, A61K9/00Cooperative ClassificationA61K9/205, A61K9/0007, A61K31/445, A61K9/006European ClassificationA61K31/445, A61K9/00L6, A61K9/00M18DLegal EventsDateCodeEventDescriptionMay 23, 2011ASAssignmentOwner name: CEPHALON, INC., PENNSYLVANIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CIMA LABS INC.;REEL/FRAME:026324/0376Effective date: 20110523Jul 2, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services